Transcription factors as targets for cancer therapy
The DOI matches its Crossref record; 111 of the 111 references it cites were found in a registry or an index.
Abstract
A limited list of transcription factors are overactive in most human cancer cells, which makes them targets for the development of anticancer drugs. That they are the most direct and hopeful targets for treating cancer is proposed, and this is supported by the fact that there are many more human oncogenes in signalling pathways than there are oncogenic transcription factors. But how could specific transcription-factor activity be inhibited?
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“STAT3 is a member of a family of seven proteins known to play critical roles in cytokine and growth factor signaling (Darnell, 2002).”
From Targeting Janus Kinases and Signal Transducer and Activator of Transcription 3 To Treat Inflammation, Fibrosis, and Cancer: Rationale, Progress, and Caution (2020) · cites this paper as Darnell, 2002
Citations
Cites
1 retracted
Aoki, N., & Matsuda, T. (2002) · Molecular Endocrinology · doi:10.1210/mend.16.1.0761 · Cited by 119
RetractedHanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Molecular portraits of human breast tumours
Perou, C. M., Sørlie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., Rees, C. A., Pollack, J. R., Ross, D. T., Johnsen, H., Akslen, L. A., et al. (2000) · Nature · doi:10.1038/35021093 · Cited by 16,261
Notch Signaling: Cell Fate Control and Signal Integration in Development
Artavanis-Tsakonas, S., Rand, M. D., & Lake, R. J. (1999) · Science · doi:10.1126/science.284.5415.770 · Cited by 5,909
Darnell, J. E. (1997) · Science · doi:10.1126/science.277.5332.1630 · Cited by 3,979
HOW CELLS RESPOND TO INTERFERONS
Stark, G. R., Kerr, I. M., Williams, B. R. G., Silverman, R. H., & Schreiber, R. D. (1998) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.67.1.227 · Cited by 3,932
Rosenwald, A., Wright, G., Chan, W. C., Connors, J. M., Campo, E., Fisher, R. I., Gascoyne, R. D., Muller-Hermelink, H. K., Smeland, E. B., Giltnane, J. M., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012914 · Cited by 3,829
Blume-Jensen, P., & Hunter, T. (2001) · Nature · doi:10.1038/35077225 · Cited by 3,738
STATs: transcriptional control and biological impact
Levy, D. E., & Darnell, J. E. (2002) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm909 · Cited by 3,201
Dérijard, B., Hibi, M., Wu, I.-H., Barrett, T., Su, B., Deng, T., Karin, M., & Davis, R. J. (1994) · Cell · doi:10.1016/0092-8674(94)90380-8 · Cited by 3,188
Cited by
Items 701–800 of 1,001
Ivanov, V. N., Partridge, M. A. K., Huang, S. X. L., & Hei, T. K. (2010) · Journal of Cellular Biochemistry · doi:10.1002/jcb.22934 · Cited by 20
mRNA interactions with disordered regions control protein activityPreprint
Luo, Y., Pratihar, S., Horste, E., Mitschka, S., Mey, A. S. J. S., Al‐Hashimi, H. M., & Mayr, C. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.02.18.529068 · Cited by 18
“It is commonly believed that transcription factors interact with their binding partners in the nucleus 25,26 .”
Synthetic CRISPR Networks Driven by Transcription Factors via Structure-Switching DNA Translators
Capelli, L., Marzari, S., Spezzani, E., & Bertucci, A. (2025) · Journal of the American Chemical Society · doi:10.1021/jacs.5c06913 · Cited by 21
“68 Following the results obtained with the TBP-Translators, we applied analogous rational design principles to optimize the stem-loop composition and length for the Myc-Max translator.”
Design, synthesis and evaluation of XZH-5 analogues as STAT3 inhibitors
Daka, P., Liu, A., Karunaratne, C. V., Csatary, E. E., Williams, C., Xiao, H., Lin, J., Xu, Z., Page, R. C., & Wang, H. (2015) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2015.01.025 · Cited by 20
An SVM-based method for assessment of transcription factor-DNA complex models
Corona, R. I., Sudarshan, S., Aluru, S., & Guo, J. (2018) · BMC Bioinformatics · doi:10.1186/s12859-018-2538-y · Cited by 17
A Drosophila model of oral peptide therapeutics for adult intestinal stem cell tumors
Bajpai, A., Ahmad, Q. T., Tang, H.-W., Manzar, N., Singh, V. P., Thakur, A. K., Ateeq, B., Perrimon, N., & Sinha, P. (2020) · Disease Models & Mechanisms · doi:10.1242/dmm.044420 · Cited by 18
“While cancer-promoting rogue kinases are 63 amenable to inhibition by small molecules, others, such as transcription factors and co-factors, 64 are largely considered undruggable (7, 8).”
BackgroundProteolysis-targeting chimeras in biotherapeutics: Current trends and future applications
Li, Q., Zhou, L., Qin, S., Huang, Z., Li, B., Li, B., Yang, M., Nice, E. C., Zhu, H., & Huang, C. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115447 · Cited by 17
Wands, A. M., Wang, N., Lum, J. K., Hsieh, J., Fierke, C. A., & Mapp, A. K. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.207589 · Cited by 18
Transcriptional tools: Small molecules for modulating CBP KIX‐dependent transcriptional activators
Bates, C. A., Pomerantz, W. C. K., & Mapp, A. K. (2010) · Biopolymers · doi:10.1002/bip.21548 · Cited by 22
Registered report: BET bromodomain inhibition as a therapeutic strategy to target c-Myc
Kandela, I. K., Jin, H. Y., Owen, K. A., & Reproducibility Project: Cancer Biology (2015) · eLife · doi:10.7554/elife.07072 · Cited by 20
“Bromodomain and extraterminal (BET) proteins are transcriptional regulators that epigenetically control the expression of genes involved in cell cycle, growth and inflammation (Darnell, 2002; Wu and Chiang, 2007; LeRoy et al., 2008; Dey et al., 2009; Nicodeme et al., 2010).”
BackgroundInfluentialGarcía, Y. R., Pabón-Martínez, Y. V., Rjh, S., & Madder, A. (2017) · Chemical Communications · doi:10.1039/c7cc01705g · Cited by 19
Transcription factor‐microRNA associations and their impact on colorectal cancer survival
Mullany, L. E., Herrick, J. S., Wolff, R. K., Stevens, J. R., Samowitz, W. S., & Slattery, M. L. (2017) · Molecular Carcinogenesis · doi:10.1002/mc.22698 · Cited by 18
Therapeutic targeting of oncogenic transcription factors by natural products in eye cancer
Zhang, M. G., Lee, J. Y., Gallo, R. A., Tao, W., Tse, D., Doddapaneni, R., & Pelaez, D. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.11.033 · Cited by 17
“Three groups of transcription factors are known to play important roles in cancer [18].”
BackgroundZhang, Z., Bu, H., Yu, J., Chen, Y., Pei, C., Li, Y., Huang, X., Tan, G., & Tan, Y. (2019) · Theranostics · doi:10.7150/thno.32693 · Cited by 17
“Although few therapeutic examples are clinically successful so far, targeting transcription factors has been considered a promising and potentially successful approach to develop drugs for the treatment of cancer [42].”
BackgroundZirin, J. D., Ni, X., Sack, L. M., Yang‐Zhou, D., Hu, Y., Brathwaite, R., Bulyk, M. L., Elledge, S. J., & Perrimon, N. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1821863116 · Cited by 19
“Unfortunately, MYC has often been classified as undruggable due to the absence of a ligand-binding domain or a hydrophobic pocket suitable for a small-molecule inhibitor (3, 4).”
BackgroundPazos, E., Jiménez‐Balsa, A., Mascarenas, J. L., & Vázquez, M. E. (2011) · Chemical Science · doi:10.1039/c1sc00108f · Cited by 18
Gao, M., Dong, W., Hu, M., Yu, M., Guo, L., Lü, Q., Guo, N., & Song, L. (2010) · Journal of Cellular Biochemistry · doi:10.1002/jcb.22509 · Cited by 17
Acuña, U. M., Zi, J., Orjala, J., & de Blanco, E. J. C. (2015) · PubMed · Cited by 17
Gao, D., Xiao, Q., Zhang, M., & Li, Y. (2016) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2016.04.022 · Cited by 18
Wang, G., Jing, Y., Cao, L., Gong, C., Gong, Z., & Cao, X. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s121619 · Cited by 20
“To this end, systemic chemotherapy treatment has been the primary means of treatment but has led to consistently disappointing results with both low response rates and high toxicity.(3) Hence, it is critical to develop new compounds and novel strategies of gastric cancer therapeutics.”
Targeting the overexpressed CREB inhibits esophageal squamous cell carcinoma cell growth
Chen, P., Li, M., Hao, Q., Zhao, X., & Hu, T. (2017) · Oncology Reports · doi:10.3892/or.2017.6167 · Cited by 16
STAT3 signaling in pancreatic ductal adenocarcinoma: a candidate therapeutic target
Al‐Hetty, H. R. A. K., Abdulameer, S. J., Alkubaisy, S. A., Zaid, S. A., Jalil, A. T., & Jasim, I. K. (2023) · Pathology - Research and Practice · doi:10.1016/j.prp.2023.154425 · Cited by 17
Aswani, B. S., Hegde, M., Vishwa, R., Alqahtani, M. S., Abbas, M., Almubarak, H. A., Sethi, G., & Kunnumakkara, A. B. (2024) · Military Medical Research · doi:10.1186/s40779-024-00564-1 · Cited by 25
“…of transcription (STAT), NF-κB, β-catenin, notch intracellular domain (NICD), AP1, hypoxia-inducible factors (HIF), myelocytomatosis oncogene (Myc), retinoblastoma binding protein (E2F), E26 transformation-specific (ETS) transcription factor and NRs has been observed in human cancers [106, 107].”
BackgroundRecent advances in exponential amplification reaction-enabled biosensors
Zhao, W., Su, F., Wang, S., Ma, Y., Li, B., & Zhang, X. (2024) · TrAC Trends in Analytical Chemistry · doi:10.1016/j.trac.2024.118006 · Cited by 16
The chemistry and pharmacology of privileged pyrroloquinazolines
Chao, B., Li, B. X., & Xiao, X. (2014) · MedChemComm · doi:10.1039/c4md00485j · Cited by 15
12 Arylstibonic acids that inhibit the DNA binding of five B-ZIP dimers
Rishi, V., Oh, W., Heyerdahl, S. L., Zhao, J., Scudiero, D. A., Shoemaker, R. H., & Vinson, C. (2010) · Journal of Structural Biology · doi:10.1016/j.jsb.2010.02.013 · Cited by 19
“Many of these B-ZIP domain containing genes are immediate early genes (IEGs) that are induced in a variety of pathologies including cancer [3].”
BackgroundCHO, S.-D., Yu, H., Park, C., Kim, S., & Cho, N. (2014) · Pharmacognosy Magazine · doi:10.4103/0973-1296.139802 · Cited by 17
“STAT3 activation was initiated upon phosphorylation and involved dimerization between two phosphorylated STAT3 monomers.[3,14,23] Thus, we investigated the effect of CT on STAT3 dimerization and found that CT clearly reduced STAT3 dimerization, which is consistent with the findings from a previous report.”
BackgroundResultVu, T., Davidson, S.-L., Borgesi, J., Mowla, M., Jeon, T., & Shim, J. (2017) · RSC Advances · doi:10.1039/c7ra08063h · Cited by 18
Gupta, B., Ghosh, K. K., & Gupta, R. C. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802147-7.00039-5 · Cited by 26
Transcription factor stoichiometry in cell fate determination
Kumar, R., & Sharma, A. (2021) · Journal of Genetics · doi:10.1007/s12041-021-01278-2 · Cited by 18
“…signal transducer and activator of transcription 5 (STAT5), nuclear factor kappa B (subunits- c-REL, RELA, NFKB1, NFKB2 and BCL2), b-catenin, Notch, v-jun avian sarcoma virus 17 oncogene homolog (c-JUN), glioma associated oncogene (GLI), etc. are associated with many forms of cancer (Darnell 2002).”
BackgroundGuo, P., Farahat, A. A., Paul, A., Boykin, D. W., & Wilson, W. D. (2021) · Chemical Science · doi:10.1039/d1sc04720e · Cited by 16
Antitumor agents 248. Chemistry and antitumor activity of tylophorinerelated alkaloids
Wei, L., Brossi, A. R., Morris-Natschke, S. L., Bastow, K. F., & Lee, K. (2008) · Studies in natural products chemistry · doi:10.1016/s1572-5995(08)80023-3 · Cited by 16
The Jak-STAT Signal Transduction Pathway in Melanoma
Nicholas, C., & Gregory, B. (2011) · InTech eBooks · doi:10.5772/18876 · Cited by 22
Transcription Factors as Targets for Cancer Therapy: AP-1 a Potential Therapeutic Target
Leaner, V. D., Donninger, H., & Birrer, M. (2007) · Current Cancer Therapy Reviews · doi:10.2174/157339407780126665 · Cited by 19
“Associated with this is the fact that they mediate signals coming from multiple different pathways, hence inhibiting their function will likely interfere with the function of numerous signaling molecules [1].”
BackgroundVeuger, S. J., & Durkacz, B. W. (2010) · DNA repair · doi:10.1016/j.dnarep.2010.11.005 · Cited by 21
Li, T., Yang, W., Li, M., Zhang, S., Zhou, X., Zuo, M., Yuan, Q., Chen, M., & Liu, Y. (2020) · Cancer Cell International · doi:10.1186/s12935-020-1145-y · Cited by 16
Wang, C., Chen, Q., Hamajima, Y., Sun, W., Zheng, Y.-Q., Hu, X., Ondrey, F. G., & Lin, J.-Z. (2012) · 癌症:英文版 · doi:10.5732/cjc.011.10454 · Cited by 16
Synthesis and testing of a triaza-cyclopenta[b]phenanthrene scaffold as a DNA binding agent
Hooda, J., Bednarski, D. W., Irish, L., & Firestine, S. M. (2005) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2005.10.047 · Cited by 16
Masker, K. K., Golden, A. M., Gaffney, C. J., Mazack, V., Schwindinger, W. F., Zhang, W., Wang, L., Carey, D. J., & Sudol, M. (2007) · Virology · doi:10.1016/j.virol.2007.03.026 · Cited by 16
Peptide–DNA conjugates as tailored bivalent binders of the oncoprotein c-Jun
Pazos, E., Portela, C., Penas, C., Vázquez, M. E., & Mascarenas, J. L. (2015) · Organic & Biomolecular Chemistry · doi:10.1039/c5ob00318k · Cited by 15
A Step toward NRF2‐DNA Interaction Inhibitors by Fragment‐Based NMR Methods
Brüschweiler, S., Fuchs, J. E., Bader, G., McConnell, D. B., Konrat, R., & Mayer, M. (2021) · ChemMedChem · doi:10.1002/cmdc.202100458 · Cited by 15
Wang, Y., Zhang, G., Meng, Q., Huang, S., Guo, P., Leng, Q., Sun, L., Liu, G., Huang, X., & Liu, J. (2022) · Nature Communications · doi:10.1038/s41467-022-29120-y · Cited by 18
Liang, M., Lu, M., Aleem, M. T., Zhang, Y., Wang, M., Wen, Z., Song, X., Xu, L., Li, X., & Yan, R. (2022) · Veterinary Research · doi:10.1186/s13567-022-01055-8 · Cited by 17
“Transcription factors are essential in regulatory mechanisms and are increasingly being recognized as potential novel drug targets [71, 72].”
BackgroundZhang, H., Qian, X., 邓克勤, Li, C., Zheng, M., Wang, J., Huang, H., & Zhou, H. (2023) · The Analyst · doi:10.1039/d3an01414b · Cited by 15
Small-Molecule Approaches to Target Transcription Factors
Cui, H., Stilgenbauer, M., & Koehler, A. N. (2024) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-062722-012209 · Cited by 20
DSE ‐ FRET : A new anticancer drug screening assay for DNA binding proteins
Miyagi, T., Shiotani, B., Ryuya, M., Yamamoto, T., Oka, T., Umezawa, K., Ochiya, T., Takano, M., & Tahara, H. (2014) · Cancer Science · doi:10.1111/cas.12420 · Cited by 15
Talib, J., Beck, J. L., Urathamakul, T., Nguyen, C. D., Aldrich-Wright, J. R., Mackay, J. P., & Ralph, S. F. (2009) · Chemical Communications · doi:10.1039/b904751d · Cited by 15
Willis, R. E. (2011) · International Journal of Molecular Sciences · doi:10.3390/ijms13010316 · Cited by 16
“Aberrantly functioning transcription activators could fulfill this role [129].”
BackgroundCyclodextrin–peptide conjugates for sequence specific DNA binding
García, Y. R., Zelenka, J., Pabón-Martínez, Y. V., Iyer, A., Buděšínský, M., Kraus, T., Smith, C. I. E., & Madder, A. (2015) · Organic & Biomolecular Chemistry · doi:10.1039/c5ob00609k · Cited by 15
Lee, J. H., Park, S., Hwang, W., Sung, J. Y., Cho, M., Shim, J., Kim, Y.-N., & Yoon, K. (2020) · Biomolecules · doi:10.3390/biom10111521 · Cited by 16
“However, resistance emerges through various mechanisms including bypass signaling or secondary mutations [20,52,53].”
BackgroundSerine phosphorylation of the Stat5a C-terminus is a driving force for transformation
Friedbichler, K., Hoelbl‐Kovacic, A., Li, G., Bunting, K. D., Sexl, V., Gouilleux, F., & Moriggl, R. (2011) · Frontiers in bioscience · doi:10.2741/3897 · Cited by 18
“Thus, the implication of serine phosphorylation in the transforming capacity of oncogenic Stat5 could potentially be translated into a therapeutic target for hematologic malignancies since overactivated transcription factors are less numerous than upstream activators and are at a focal point in the deregulated pathway…”
BackgroundXu, K., Wang, J., Gao, J., Di, J., Jiang, B., Chen, L., Wang, Z., Wang, A., Wu, F., Wu, W., et al. (2016) · Oncology Reports · doi:10.3892/or.2016.4961 · Cited by 15
“However, GATA2 is traditionally considered to be undruggable (32).”
BackgroundDar, K. B., Bhat, A. H., Amin, S., Anjum, S., Reshi, B. A., Zargar, M. A., Masood, A., & Ganie, S. A. (2018) · Current Cancer Drug Targets · doi:10.2174/1568009618666180803104631 · Cited by 16
Alazard, R. J., Blaud, M., Elbaz, S., Vossen, C., Icre, G., Joseph, G., Nieto, L., & Erard, M. (2005) · Nucleic Acids Research · doi:10.1093/nar/gki284 · Cited by 19
Li, S., Gao, K., & Yao, D. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e33277 · Cited by 16
“Notably, the Notch signaling pathways, which were enriched among the ARDEGs, are known for their roles in cell proliferation, differentiation, and apoptosis [30].”
Exploring the utility of organo-polyoxometalate hybrids to inhibit SOX transcription factors
Narasimhan, K., Micoine, K., Lacôte, E., Thorimbert, S., Cheung, E. C. W., Hasenknopf, B., & Jauch, R. (2014) · Cell Regeneration · doi:10.1186/2045-9769-3-10 · Cited by 16
Chen, Y., Yan, X., Yang, W., Wang, J., Lu, Q., Li, B., Zhu, W., & Zhou, X. (2020) · Journal of Chromatography A · doi:10.1016/j.chroma.2020.461148 · Cited by 14
Ordinario, D. D., Burke, A. M., Phan, L., Jocson, J., Wang, H., Dickson, M. N., & Gorodetsky, A. A. (2014) · Analytical Chemistry · doi:10.1021/ac501441d · Cited by 15
Ando, T., Kudo, Y., Iizuka, S., Tsunematsu, T., Umehara, H., Shrestha, M., Matsuo, T., Kubo, T., Shimose, S., Arihiro, K., et al. (2017) · Scientific Reports · doi:10.1038/srep40187 · Cited by 14
Molecular Recognition of DNA by Py–Im Polyamides: From Discovery to Oncology
Dervan, P. B., Kurmis, A. A., & Finn, P. B. (2018) · Royal Society of Chemistry eBooks · doi:10.1039/9781788012928-00298 · Cited by 17
Differential effects, on oncogenic pathway signalling, by derivatives of the HNF4 α inhibitor BI6015
Kim, J.-H., Eom, H. J., Lim, G., Park, S., Lee, J., Nam, S., Kim, Y. H., & Jeong, J.-H. (2019) · British Journal of Cancer · doi:10.1038/s41416-018-0374-5 · Cited by 17
Yang, X., Cheng, Y., Li, X., Zhou, J., Dong, Y., Shen, B., Zhao, L., & Wang, J. (2021) · OncoTargets and Therapy · doi:10.2147/ott.s293085 · Cited by 15
“Previous studies have reported that the number of oncogenic signaling proteins that are altered in cancer outnumber oncogenic transcription factors, which indicates that transcription factors are promising therapeutic targets in tumors.(13) Although it is known that transcription factors participate in tumor occurrenc…”
BackgroundSiavash, H., Nikitakis, N. G., & Sauk, J. J. (2004) · Critical Reviews in Oral Biology & Medicine · doi:10.1177/154411130401500505 · Cited by 17
Grånäs, C., Lundholt, B. K., Loechel, F., Pedersen, H.-C., Bjørn, S. P., Linde, V., Krog-Jensen, C., Nielsen, E.-M. D., Præstegaard, M., & Nielsen, S. J. (2006) · SLAS DISCOVERY · doi:10.1177/1087057106287136 · Cited by 16
“localization of proteins, either causally or diagnostically.(26) The Redistribution technique allows the identification of compounds that modulate the translocation of proteins within the cell.”
BackgroundRajagopalan, V., Vaidyanathan, M., Janardhanam, V. A., & Bradner, J. E. (2014) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-014-0083-4 · Cited by 18
Pang, J., Li, H., Zhang, X., Luo, Z., Chen, Y., Zhao, H., Lv, H., Zheng, H., Fu, Z., Tang, W., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241713497 · Cited by 15
“Given the critical role of TFs, approximately 16% of almost 1600 TFs are implicated in a variety of cancers, including breast cancer [7,8].”
BackgroundKrajnović, M., Kožik, B., Božović, A., & Jovanović-Ćupić, S. (2023) · Cells · doi:10.3390/cells12182303 · Cited by 13
“RUNX genes can hinder or activate tumourigenesis [12].”
BackgroundRNF6 promotes gastric cancer progression by regulating CCNA1/CREBBP transcription
Jiang, Q., Miao, J., Wu, F., Li, F., Zhang, J., Jing, X., Cai, S., Ma, X., Wang, X., Zhao, L., et al. (2023) · Cell Cycle · doi:10.1080/15384101.2023.2275899 · Cited by 13
“Some transcription factors are overactive in a variety of human tumor cells, making them targets for the development of anticancer drugs [9].”
BackgroundWufuer, R., Liu, K., Feng, J., Wang, M., Hu, S., Chen, F., Lin, S., & Zhang, Y. (2024) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2024.01.031 · Cited by 12
Regulation of β-catenin transcription activity by leupaxin in hepatocellular carcinoma
Shi, J., Wu, W., Hu, G., Yu, X., Yu, G.-S., Han, L., Yang, M., Liu, B., & Wu, Z. (2015) · Tumor Biology · doi:10.1007/s13277-015-4060-4 · Cited by 15
Family of peptides synthesized in the human body have anticancer effects.
Vesely, D. L. (2014) · PubMed · Cited by 15
Wnt/β-catenin up-regulates Midkine expression in glioma cells.
Tang, S., Gao, Y.-L., & Chen, X. (2015) · Europe PMC (PubMed Central) · Cited by 13
Taking a holistic view of PEST‐containing nuclear protein (PCNP) in cancer biology
Afzal, A., Sarfraz, M., Li, G., Ji, S., Duan, S., Khan, N. H., Wu, D., & Ji, X. (2019) · Cancer Medicine · doi:10.1002/cam4.2465 · Cited by 16
ETS Fusion Genes in Prostate Cancer
Brenner, J. C., Chinnaiyan, A. M., & Tomlins, S. A. (2013) · Springer eBooks · doi:10.1007/978-1-4614-6828-8_5 · Cited by 19
Novel small molecule inhibitor of Kpnβ1 induces cell cycle arrest and apoptosis in cancer cells
Ajayi-Smith, A. F., van der Watt, P. J., Mkwanazi, N., Carden, S., Trent, J. O., & Leaner, V. D. (2021) · Experimental Cell Research · doi:10.1016/j.yexcr.2021.112637 · Cited by 14
Network pharmacology of triptolide in cancer cells: implications for transcription factor binding
Seo, E., Dawood, M., Hult, A. K., Olsson, M. L., & Efferth, T. (2021) · Investigational New Drugs · doi:10.1007/s10637-021-01137-y · Cited by 13
Weidle, U. H., Birzele, F., Ausländer, S., & Brinkmann, U. (2021) · Anticancer Research · doi:10.21873/anticanres.15223 · Cited by 13
Han, L., WU, Z., & Zhao, Q. (2014) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2014.1620 · Cited by 14
“The list of transcription factors in most human cancer cells is limited and these factors usually serve as targets for anticancer drugs development (41).”
Nitric Oxide−Releasing Hybrid Drugs Target Cellular Processes Through S-Nitrosylation
Kashfi, K. (2012) · Forum on Immunopathological Diseases and Therapeutics · doi:10.1615/forumimmundisther.2012006099 · Cited by 13
Xiong, Y., Lin, L., Zhang, X., & Wang, G. (2016) · RSC Advances · doi:10.1039/c6ra00701e · Cited by 13
Abou‐Elkhair, R. A. I., Hassan, A. E. A., Boykin, D. W., & Wilson, W. D. (2016) · Organic Letters · doi:10.1021/acs.orglett.6b02359 · Cited by 13
Xu, X., Wang, L., Zhu, D., Wang, Y., & Jiang, W. (2018) · Talanta · doi:10.1016/j.talanta.2018.04.047 · Cited by 13
Small molecule binders recognize DNA microstructural variations via an induced fit mechanism
Carter, E. K., Laughlin, S., Dodd, T., Wilson, W. D., & Ivanov, I. N. (2019) · Physical Chemistry Chemical Physics · doi:10.1039/c8cp05537h · Cited by 14
Molecular Underpinnings Governing Genetic Complexity of ETS-Fusion-Negative Prostate Cancer
Bhatia, V., & Ateeq, B. (2019) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2019.07.001 · Cited by 15
Hong, W., Hu, Y., Fan, Z., Gao, R., Yang, R., Bi, J., & Hou, J. (2019) · Oncology Letters · doi:10.3892/ol.2019.11171 · Cited by 14
“It is therefore crucial to determine the underlying mechanisms of HCC relapse, in order to increase the overall survival of patients with HCC. Transcription factors (TFs) serve crucial roles in the regulation of tumor progression (6-8).”
Ng, P. Y., Tang, Y., Knosp, W. M., Stadler, H. S., & Shaw, J. T. (2007) · Angewandte Chemie · doi:10.1002/ange.200700762 · Cited by 13
p53 mediates a default programme of mammary gland involution in the absence of STAT3
Matthews, J. R., & Clarke, A. R. (2005) · Oncogene · doi:10.1038/sj.onc.1208512 · Cited by 13
Zhang, Y., Ho, M., Zhuo, H., Min, X., Yao, Q., Gu, A.-Q., Wu, S., Zhang, D.-B., Lu, J., Chen, Y., et al. (2017) · Acta Haematologica · doi:10.1159/000455939 · Cited by 13
Concordant overexpression of phosphorylated ATF2 and STAT3 in extramammary Paget’s disease
Chen, S., Takeuchi, S., Moroi, Y., Hayashida, S., Makiko, K. I. D. O., Tomoeda, H., Uenotsuchi, T., Tu, Y., Furue, M., & Urabe, K. (2008) · Journal of Cutaneous Pathology · doi:10.1111/j.1600-0560.2008.01076.x · Cited by 13
“ATF2/activated protein 1 (AP-1) and STAT3 have been identified as important tumorigenic factors.(25) P-ATF2 upregulates genes that contribute to tumorigenesis(11,26) upon activation in stress-activated protein kinase/c-jun N-terminal kinase (SAPK/JNK) or rat sarcoma virus oncogene-MAPK/ERK kinase-extracellular-signal…”
BackgroundChemical modulation of transcription factors
Wiedemann, B. M., Weisner, J., & Rauh, D. (2018) · MedChemComm · doi:10.1039/c8md00273h · Cited by 12
ZFP64 transcriptionally activates PD-1 and CTLA-4 and plays an oncogenic role in esophageal cancer
Qiu, G., & Deng, Y. (2022) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2022.06.011 · Cited by 12
Multilabel all-relevant feature selection using lower bounds of conditional mutual information
Teisseyre, P., & Lee, J. (2022) · Expert Systems with Applications · doi:10.1016/j.eswa.2022.119436 · Cited by 12
Activation of Bivalent Gene POU4F1 Promotes and Maintains Basal‐like Breast Cancer
Zhang, J., Miao, N., Lao, L., Deng, W., Wang, J., Zhu, X., Huang, Y., Lin, H., Zeng, W., Zhang, W., et al. (2024) · Advanced Science · doi:10.1002/advs.202307660 · Cited by 14
Calles, A., Calvo, E., Núñez, G. S., Costanzo, F., Navarro, M. J. G., Martínez, M., Gupta, A., Cuevas, C., Egly, J., & Aviles, P. M. (2024) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-24-0050 · Cited by 15
“As DNA processing mechanisms, including transcription and replication, are intimately involved when dysregulated by pathogenesis, they are among the most straightforward targets for disrupting cancer evolution (24).”
The arylstibonic acid compound NSC13746 disrupts B-ZIP binding to DNA in living cells
Heyerdahl, S. L., Rozenberg, J. M., Jamtgaard, L., Rishi, V., Varticovski, L., Akah, K., Scudiero, D. A., Shoemaker, R. H., Karpova, T., Day, R. N., et al. (2010) · European Journal of Cell Biology · doi:10.1016/j.ejcb.2009.11.029 · Cited by 12
“In addition, upstream oncogenic mutations in serinethreonine kinase cascades can phosphorylate downstream nuclear B-ZIP transcription factors resulting in their chronic activation which makes them potential drug targets even though they themselves are not mutated (Darnell, 2002).”
BackgroundZhu, D., Wang, L., Xu, X., & Jiang, W. (2016) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2016.09.073 · Cited by 12
Elumalai, N., Natarajan, K., & Berg, T. (2017) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2017.05.039 · Cited by 12
Shinde, D. A., Albino, D., Zoma, M., Mutti, A., Mapelli, S. N., Civenni, G., Kokanovic, A., Merulla, J., Pérez‐Escuredo, J., Costales, P., et al. (2018) · European Urology Oncology · doi:10.1016/j.euo.2018.08.024 · Cited by 12
Galán‐Martínez, J., Stamatakis, K., Sánchez‐Gómez, I., Vázquez‐Cuesta, S., Gironès, N., & Fresno, M. (2021) · Molecular Oncology · doi:10.1002/1878-0261.13085 · Cited by 14
Stapled peptides as potential inhibitors of SARS‐CoV‐2 binding to the hACE2 receptor
Tzotzos, S. J. (2022) · Journal of Peptide Science · doi:10.1002/psc.3409 · Cited by 11
“Transcription factors, which play a major role in regulation of cell state and neoplastic growth, are considered prime candidates as drug targets.([9]) Use of stapled peptides to target the interaction of transcription factors was reported in earlier research of Moellering et al.”
Result
Metadata
- Authors
- Darnell, J. E.
- Venue
- Nature Reviews Cancer
- Published
- 2002-10
- Volume
- 2
- Issue
- 10
- Pages
- 740-749
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W1980480652
- Cited by
- 1,194
- References
- 109
- Citations by year
- 2026: 29 · 2025: 37 · 2024: 41 · 2023: 48 · 2022: 37 · 2021: 45 · 2020: 48 · 2019: 48 · 2018: 47 · 2017: 64 · 2016: 50 · 2015: 77 · 2014: 76 · 2013: 87 · 2012: 73
- FWCI
- 3.93
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- transcription factors, cancer therapy, anticancer drug targets, oncogenes, oncogenic transcription factor, signaling pathways, transcription factor inhibition
- MeSH terms
- Antineoplastic Agents, Cytoplasm, Cytoskeletal Proteins, Humans, Ligands, Models, Biological, Mutation, Neoplasms, Protein Binding, Proto-Oncogene Proteins, Transcription Factors, Transcription, Genetic, Signal Transduction, Trans-Activators, NF-kappa B, Apoptosis, Zebrafish Proteins, Wnt Proteins, beta Catenin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.